Type of information: Company acquisition
Acquired company: Syncom (The Netherlands)
Acquiring company: Mercachem (The Netherlands)
- • On August 28, 2017, Mercachem and Syncom, two Dutch
drug discovery Contract Research Organizations (CRO), announced that the two companies are joining forces effective immediately. The resulting Mercachem-Syncom Group, with more than 300 employees and operations in Nijmegen and Groningen, the Netherlands and Prague, Czech Republic, becomes the premier European mid-sized CRO offering innovative best-in-class chemistry solutions.
- The merger of Mercachem and Syncom and the Group’s growth strategy with a further expansion both organically as well as
through partnerships and further acquisitions is supported by Gilde Healthcare, a leading investor in healthcare
together with Dutch pension fund service provider PGGM, as co-investor.
- Since their inception in 1997 and 1988 respectively, Mercachem and Syncom have focused on high-quality chemistry services to large and mid-size pharmaceutical, life sciences and innovative chemistry customers worldwide. The merger enables the
new group to broaden its offering of integrated drug discovery services and invest into state-of the-art knowledge base and facilities to address clients’ growing demand for outsourcing solutions.
The Mercachem-Syncom Group has also developed independently novel chemical matter in a number of areas, including CDK8 and sumoylation inhibitors which will be further developed in milestone-based partnerships.
Related: CRO - Technology - Services